Surrozen, Inc (SRZN): Price and Financial Metrics


Surrozen, Inc (SRZN): $0.71

0.00 (-0.45%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SRZN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SRZN Stock Price Chart Interactive Chart >

Price chart for SRZN

SRZN Price/Volume Stats

Current price $0.71 52-week high $3.97
Prev. close $0.71 52-week low $0.34
Day low $0.70 Volume 166,096
Day high $0.75 Avg. volume 742,485
50-day MA $0.61 Dividend yield N/A
200-day MA $2.13 Market Cap 24.82M

Surrozen, Inc (SRZN) Company Bio


Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 that stimulates hepatocyte regeneration, improves liver function, and reduces fibrosis; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are highly expressed in intestinal crypts. The company was founded in 2016 and is headquartered in South San Francisco, California.


SRZN Latest News Stream


Event/Time News Detail
Loading, please wait...

SRZN Latest Social Stream


Loading social stream, please wait...

View Full SRZN Social Stream

Latest SRZN News From Around the Web

Below are the latest news stories about SURROZEN INC that investors may wish to consider to help them evaluate SRZN as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday!

William White on InvestorPlace | December 15, 2022

Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today reported financial results for the third quarter of 2022 and provided a corporate update. SZN-1326 UpdateSurrozen announced today that it voluntarily paused enrollment in the single ascending dose (SAD) portion of the Company’s Phase 1 clinical tria

Yahoo | November 14, 2022

Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week

SZN-043 preclinical data shows rapid, transient increases in hepatocyte proliferation and was well tolerated in non-clinical toxicology studiesSZN-1326 preclinical data shows improved intestinal epithelial healing, restored epithelial barrier, and reduced colitis-associated collagen deposition and was well tolerated in non-clinical toxicology studies SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering ta

Yahoo | October 10, 2022

Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases

The collaboration and licensing agreement is Surrozen’s first strategic partnership for one of its compounds in developmentSurrozen's novel antibody-based approach targets Fzd4 biology, which has been shown to play a fundamental role in retinal vascular integrity and functionThe new partnership combines Surrozen’s proprietary SWAP™ technology for modulating Wnt signaling with Boehringer Ingelheim’s research and development expertise to develop a first-in-class treatment for patients with eye dis

Yahoo | October 6, 2022

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy

Results highlight a potential novel treatment for diabetic and other retinopathiesUnique Wnt-mediated mechanism increases vascular integrity, and transforms pathologic regrowth into physiological regrowth of retinal blood vessels SOUTH SAN FRANCISCO, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, announced today the publication of an article by Surro

Yahoo | September 26, 2022

Read More 'SRZN' Stories Here

SRZN Price Returns

1-mo 22.01%
3-mo -65.87%
6-mo -76.25%
1-year -70.29%
3-year N/A
5-year N/A
YTD 22.01%
2022 -90.96%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.646 seconds.